We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
AB Corporate Bond ETF | NASDAQ:EYEG | NASDAQ | Exchange Traded Fund |
Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 35.32 | 14.21 | 56.15 | 0 | 09:09:40 |
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue.
See
Instruction 1(b).
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
|
OMB APPROVAL
OMB Number: 3235-0287 Estimated average burden hours per response... 0.5 |
|
|
|
1. Name and Address of Reporting Person
*
ARMISTICE CAPITAL, LLC |
2. Issuer Name
and
Ticker or Trading Symbol
EYEGATE PHARMACEUTICALS INC [ EYEG ] |
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director __ X __ 10% Owner _____ Officer (give title below) _____ Other (specify below) |
510 MADISON AVENUE, 22ND FLOOR |
3. Date of Earliest Transaction
(MM/DD/YYYY)
|
|
NEW YORK, NY 10022 |
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
___ Form filed by One Reporting Person _ X _ Form filed by More than One Reporting Person |
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned |
||||||||||
1.Title of Security
(Instr. 3) |
2. Trans. Date | 2A. Deemed Execution Date, if any |
3. Trans. Code
(Instr. 8) |
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) |
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) |
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |||
Code | V | Amount | (A) or (D) | Price |
Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) |
|||||||||||||||
1. Title of Derivate Security
(Instr. 3) |
2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any |
4. Trans. Code
(Instr. 8) |
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) |
6. Date Exercisable and Expiration Date |
7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) |
8. Price of Derivative Security
(Instr. 5) |
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | ||||
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||||||
Warrants | $1.50 | 6/14/2017 (3) | 6/14/2022 | Common Stock | 2000000 | 2000000 | D (1) | ||||||||
Warrants | $0.32 | 4/17/2018 (4) | 4/17/2023 | Common Stock | 15937500 | 15937500 | D (1) | ||||||||
Warrants | $0.32 | 4/17/2018 (4) | 4/17/2023 | Common Stock | 0 | 15937500 | I | See Footnote (2) | |||||||
Warrants | $0.32 | 4/17/2018 (4) | 4/17/2023 | Common Stock | 0 | 15937500 | I | See Footnote (2) | |||||||
Series C Convertible Peferred Stock | $0.32 | 4/17/2018 (5) | (5) | Common Stock | 12787500 | 12787500 | D (1) | ||||||||
Series C Convertible Preferred Stock | $0.32 | 4/17/2018 (5) | (5) | Common Stock | 0 | 12787500 | I | See Footnote (2) | |||||||
Series C Convertible Preferred Stock | $0.32 | 4/17/2018 (5) | (5) | Common Stock | 0 | 12787500 | I | See Footnote (2) |
Remarks:
Armistice Capital, LLC and Steven Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interest therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. |
Reporting Owners
|
|||||
Reporting Owner Name / Address |
|
||||
Director | 10% Owner | Officer | Other | ||
ARMISTICE CAPITAL, LLC
510 MADISON AVENUE, 22ND FLOOR NEW YORK, NY 10022 |
|
X |
|
|
|
Armistice Capital Master Fund Ltd.
510 MADISON AVENUE, 22ND FLOOR NEW YORK, NY 10022 |
|
X |
|
|
|
Boyd Steven
510 MADISON AVENUE, 22ND FLOOR NEW YORK, NY 10022 |
|
X |
|
|
Signatures
|
||
Armistice Capital, LLC, By: /s/ Steven Boyd, Managing Member | 4/18/2018 | |
** Signature of Reporting Person |
Date
|
|
Armistice Capital Master Fund, Ltd., By:/s/ Steven Boyd, Director | 4/18/2018 | |
** Signature of Reporting Person |
Date
|
|
/s/ Steven Boyd | 4/18/2018 | |
** Signature of Reporting Person |
Date
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | |
* | If the form is filed by more than one reporting person, see Instruction 4(b)(v). |
** | Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
Note: | File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. |
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. |
1 Year AB Corporate Bond ETF Chart |
1 Month AB Corporate Bond ETF Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions